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Carol M. Artlett1, Sihem Sassi-Gaha1, Ronald C. Ramos2,4, Frederick W. Miller3 and Lisa G. Rider3*
Abstract
Introduction: Microchimeric cells have been studied for over a decade, with conflicting reports on their presence
and role in autoimmune and other inflammatory diseases. To determine whether microchimeric cells were
pathogenic or mediating tissue repair in inflammatory myopathies, we phenotyped and quantified microchimeric
cells in juvenile idiopathic inflammatory myopathies (JIIM), muscular dystrophy (MD), and noninflammatory control
muscle tissues.
Method: Fluorescence immunophenotyping for infiltrating cells with sequential fluorescence in situ hybridization
was performed on muscle biopsies from ten patients with JIIM, nine with MD and ten controls.
Results: Microchimeric cells were significantly increased in MD muscle (0.079 ± 0.024 microchimeric cells/mm2
tissue) compared to controls (0.019 ± 0.007 cells/mm2 tissue, p = 0.01), but not elevated in JIIM muscle
(0.043 ± 0.015 cells/mm2). Significantly more CD4+ and CD8+ microchimeric cells were in the muscle of patients
with MD compared with controls (mean 0.053 ± 0.020/mm2 versus 0 ± 0/mm2 p = 0.003 and 0.043 ± 0.023/mm2
versus 0 ± 0/mm2 p = 0.025, respectively). No differences in microchimeric cells between JIIM, MD, and noninflammatory
controls were found for CD3+, Class II+, CD25+, CD45RA+, and CD123+ phenotypes, and no microchimeric cells were
detected in CD20, CD83, or CD45RO populations. The locations of microchimeric cells were similar in all three
conditions, with MD muscle having more microchimeric cells in perimysial regions than controls, and JIIM having
fewer microchimeric muscle nuclei than MD. Microchimeric inflammatory cells were found, in most cases, at
significantly lower proportions than autologous cells of the same phenotype.
Conclusions: Microchimeric cells are not specific to autoimmune disease, and may not be important in muscle
inflammation or tissue repair in JIIM.
Introduction
The role of microchimeric cells in health and disease has
been controversial. Microchimeric cells are acquired
during pregnancy, with the transfer of cells from fetus to
mother or mother to fetus. Microchimeric cells have
been documented to be elevated in the peripheral blood
and affected tissues of patients with autoimmune
diseases, such as systemic sclerosis [1], systemic lupus
erythematosus [2], neonatal lupus [3], and juvenile
idiopathic inflammatory myopathies (JIIM) [4–6]. Re-
cently, microchimeric cells were found to be elevated in
specific target tissues, such as the liver in hepatitis C in-
fection [7] and tumors, such as HER2-positive breast
cancer, cervical, lung and thyroid cancer, and melanoma
[8–10]. However, not all studies have documented higher
levels of chimeric cells in autoimmune conditions [11]
or cancer [12]. This variability suggests that they might
be recruited nonspecifically to sites of inflammation and
tissue injury [13, 14] or participate in tissue repair [8].
The JIIM are systemic autoimmune diseases character-
ized by chronic muscle inflammation and weakness.
Juvenile dermatomyositis (JDM), the form of JIIM with
characteristic photosensitive skin rashes, including
Gottron’s papules and heliotrope rash, is the most
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common of the JIIM and is thought to be mediated
by CD4+ T cells, B cell and dendritic cell attack on
muscle capillaries, whereas juvenile polymyositis
(JPM), the form of JIIM without characteristic rashes,
is thought to be mediated by CD8+ T cells on myofi-
bers [15–17]. We previously found elevated levels of
maternal microchimeric cells in muscle biopsies and
peripheral blood of boys with JIIM and characterized
these cells to be in the CD4+ and CD8+ peripheral
T cells [4]. However, the phenotypes of the microchi-
meric cells in affected muscle tissues were not inves-
tigated. The current study analyzes the frequency of
microchimeric cells within different inflammatory pheno-
types in the muscle of JIIM and compares these findings
with the nonautoimmune inflammatory muscle disorder
muscular dystrophy (MD) [18] and with noninflamma-
tory control (NIC) muscle tissue. We sought to deter-
mine whether microchimeric cells have a pathogenic or
reparative role in JIIM.
Methods
Patients
All studies were performed with full Institutional Review
Board approval from the National Institutes of Health
and waived approval from the Institutional Review Board
at Drexel University College of Medicine. All patients
consented to the study. Muscle biopsies were obtained
for diagnosis, and prior to initiation of therapy, from ten
patients with JIIM (six JDM, four JPM), nine MD (eight
Duchenne, one Becker dystrophy) and ten controls
without inflammatory disease (four mitochondrial myop-
athies, six histologically normal) and analyzed by
immunofluorescence for specific phenotypes and by
fluorescence in situ hybridization (FISH) for maternal
microchimeric cells. The ages of the JIIM patients
ranged from 3 to 16 years [15, 16], the patients with MD
from 2 to 14 years [19], and the controls from 2 to 17
years. All tissues were paraffin embedded and derived
from males and were cut at 5 μM. No patient had prior
blood transfusions. The size of the tissue sample ranged
from 9 to 96 mm2 in JIIM, 6 to 245 mm2 in MD, and 20
to 62 mm2 in the controls.
Immunofluorescence/fluorescence in situ hybridization
Before immunofluorescent staining was performed, one
slide from each biopsy was stained with hematoxylin
and eosin to verify the histological appearance of the tis-
sue and the presence of inflammatory cells. Biopsies
were selected based on infiltration density. The immuno-
fluorescent assessment of the tissues was performed first,
and all positive cells of each immunophenotype were docu-
mented. Tissues were stained for T cells (CD3, CD4, and
CD8), T cell activation markers (CD25 and HLA Class II),
memory T cells (CD45RO), naïve T cells (CD45RA), B cells
(CD20) and dendritic cells (CD123 and CD83) by using
antibodies from Neomarkers (Fremont, CA, USA) or Dako
(Carpinteria, CA, USA). The secondary antibody carrying
the Cy-2 conjugate (Jackson ImmunoResearch, West
Grove, PA, USA) was used to detect the primary antibody,
and sections were mounted with DAPI and viewed with a
Nikon epi-fluorescent microscope with triple-band filter at
1000× magnification (Nikon Instruments, Melville, NY,
USA). Positive cells were documented, and sections were
processed for FISH analysis as we described previously [1].
Cells that had XX or XY nuclear probes were quantified.
The sections were also assessed after FISH for other nuclei
that were carrying XX probes but were negative for im-
munofluorescent stain. Muscle fiber nuclei were docu-
mented by morphological analyses of the muscle fiber
based on the location and shape of the nucleus within the
fiber. The myogenic origin was confirmed in 12 sections by
actin staining. Personnel involved with muscle biopsy stud-
ies were blinded to patient diagnosis.
Characterization of microchimeric or autologous cells
was determined only when both probes were evident in
the nucleus (XX for microchimeric cells and XY for
autologous cells). We performed immunofluorescence
prior to FISH and stained the protein green. Because
some immunofluorescence signal can remain after the
FISH procedure, we selected red for the X chromosome.
This approach left no doubt about the presence of a
microchimeric cell, even if residual immunofluorescence
staining was present. Biopsy sections were selected to
limit the number of overlapping nuclei in the inflamma-
tory cell infiltrates, because overlapping nuclei could re-
sult in false assignment of microchimerism due to two X
chromosome probes appearing to be in the same nu-
cleus when they are in separate nuclei. Prior to making
the final assessment as to whether a cell was microchi-
meric or not, the entire nucleus of the cell was assessed
for the presence of other probes, i.e., possible nuclei
lying underneath. Only when it was confirmed that no
additional probes were present, were the nuclei assigned
as being microchimeric or autologous. Twelve (JIIM or
MD) biopsies with many overlapping infiltrating cells
without well-defined nuclei were excluded. With this
careful approach to immunophenotyping and FISH we
reduced the chance of over-identifying microchimeric
cells due to overlapping cells and to fluorescent protein
remaining after the phenotyping.
Statistical analyses
Results obtained by FISH were expressed as mean ±
standard error of the mean. Differences in the frequency
of positive microchimeric cells in the tissue were evalu-
ated using Prism 5 software (GraphPad Software, San
Diego, CA, USA). For nonparametric data, the Mann–
Whitney rank sum t test was used to compare quantities
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of microchimeric cells. A p value ≤ 0.05 was considered
significant; due to small sample sizes, p = 0.051–0.06 was
considered to demonstrate a trend toward significance.
Results
Are microchimeric cells enriched in inflammatory diseases
and what are their phenotypes?
Microchimeric cells were detected in nine of ten JIIM
muscle biopsies, nine of nine MD biopsies, and eight of
ten NIC biopsies (ten sections per biopsy). Of the
total phenotyped and nonphenotyped microchimeric
cells across all sections examined, the density was
0.043 ± 0.015 microchimeric cells/mm2 of muscle tissue in
JIIM, 0.079 ± 0.024/mm2 of tissue in MD, and 0.019 ±
0.007/mm2 of tissue in NICs (Fig. 1a). MD biopsies had
significantly more microchimeric cells/mm2 than controls
(p = 0.01). There was a trend toward more microchimeric
cells/mm2 of muscle tissue in MD patients compared to
JIIM (p = 0.06), but there was no difference in the density
of microchimeric cells between JIIM and controls.
There were few differences in the phenotypes of the
microchimeric cells and no differences in the concentration
of microchimeric cells/mm2 of muscle tissue in CD3+, Class
II+, CD45RA+ or CD123+ phenotypes in patients with
JIIM, MD or the controls (Fig. 1b, e, g, h). There were sig-
nificantly more CD4+ and CD8+ microchimeric cells in
the muscle of patients with MD compared with controls
(0.053 ± 0.020/mm2 vs. 0 ± 0/mm2 for CD4+ microchi-
meric cells [Fig. 1c, p = 0.003] and 0.043 ± 0.023/mm2 vs.
0 ± 0/mm2 for CD8+ microchimeric cells [Fig. 1d,
Fig. 1 Density of microchimeric cells by immunophenotype in the muscle of patients with juvenile idiopathic inflammatory myopathies (JIIM),
muscular dystrophy (MD) and noninflammatory controls (N-IC). Data are presented as mean ± standard error of the mean for each immunophenotype.
No microchimeric cells were identified that were positive for CD20, CD45RO or CD83 (data not shown). JIIM juvenile idiopathic inflammatory myopathy
(n = 10), MD muscular dystrophy (n = 9), N-IC noninflammatory controls (n = 10). *p = 0.01; **p = 0.025; ***p = 0.003; ****p = 0.006. (a) Total microchimeric
cells in tissues; (b) CD3 positive microchimeric cells; (c) CD4 positive microchimeric cells; (d) CD8 positive microchimeric cells; (e) HLA class II positive
microchimeric cells; (f) CD25 positive microchimeric cells; (g) CD45RA positive microchimeric cells; (h) CD123 positive microchimeric cells
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p = 0.025]). There was a trend toward more CD4+ micro-
chimeric cells in MD biopsies compared with JIIM (0.053 ±
0.020/mm2 vs. 0.012 ± 0.006/mm2, p = 0.06); whereas the
number of CD4+ microchimeric cells did not differ between
JIIM and controls. The number of CD8+ microchimeric
cells did not differ in the muscle tissue of patients with MD
and JIIM, or JIIM and controls. MD muscle tissue had sig-
nificantly more microchimeric CD25+ cells/mm2 of tissue
(0.038 ± 0.014/mm2), whereas JIIM patients and controls
did not have any detectable CD25+ microchimeric cells
(Fig. 1f). None of the biopsies had microchimeric cells that
were CD20+, CD45RO+ or CD83+ (not shown). Examples
of phenotyped microchimeric cells are depicted in Fig. 2.
There were few differences in concentration of micro-
chimeric cells/mm2 in the JIIM subsets (not shown).
JPM had more CD8+ microchimeric cells/mm2 than
JDM (0.064 + 0.046/mm2 vs. 0 ± 0/mm2; p = 0.025) and
controls (0.064 + 0.046/mm2 vs. 0 ± 0/mm2, p = 0.004) but
had similar numbers of CD8+ microchimeric cells/mm2 as
MD (p = 0.51). CD4+ microchimeric cells were detected in
JDM, but not in JPM, muscle (0.022 ± 0.009/mm2 vs.
0 ± 0/mm2), but the concentrations did not differ
significantly (p = 0.31).
Does the location of microchimeric cells differ among
inflammatory muscle diseases?
Overall, 62.2 ± 5.7 % of all microchimeric cells were in
the endomysial region, 26.5 ± 4.9 % in the perimysial re-
gions and 11.3 ± 4.2 % in the perivascular regions. There
were no significant differences between the percentages
of microchimeric cells in the perivascular regions of
JIIM or MD patients or the NIC subjects (20.8 ± 10.6 %
in JIIM, 8.2 ± 4.1 % in MD, and 3.7 ± 3.5 % in controls;
Fig. 3a). In the perimysial regions, microchimeric cells
occurred in similar proportions between JIIM and MD
patients (25.8 ± 7.4 % vs. 38.1 ± 5.6 %, p = 0.62) and be-
tween JIIM and controls (25.8 ± 7.4 % vs. 15.6 ± 10.8 %,
p = 0.14). However, biopsies from MD patients had a
higher percentage of microchimeric cells in the peri-
mysial region than controls (33.9 ± 5.5 % vs. 14.0 ± 10.3 %,
p = 0.014; Fig. 3b). There were no differences in the
endomysial regions between JIIM or MD patients or
Fig. 2 Representative microchimeric cells that are expressing an immunophenotype in the muscle of patients with muscular dystrophy and
juvenile idiopathic inflammatory myopathies. Examples of microchimeric cells that express a phenotype are depicted, the left panel in each pair is
the phenotype and the right panel is the corresponding FISH result for that cell. JIIM juvenile idiopathic inflammatory myopathy, MD muscular
dystrophy, V vessel. Star denotes the phenotype-positive cell (green) and the arrows indicate the XX probes (red) within that phenotyped cell
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controls (53.3 ± 10.1 % in JIIM, 53.7 ± 5.3 % in MD,
and 80.7 ± 10.8 % in controls; Fig. 3c).
The subsets of JIIM (not shown) did not differ in the
percentages of microchimeric cells in the perivascular
regions (14.6 ± 11.0 % in JPM vs. 25.0 ± 17.1 % in JDM,
p = 0.90), perimysial regions (41.7 ± 4.6 % in JPM vs.
15.3 ± 10.2 % in JDM, p = 0.15) and endomysial regions
(43.8 ± 11.9 % in JPM vs. 59.7 ± 15.6 % in JDM, p = 0.51).
Do microchimeric cells drive disease?
For each phenotype we determined whether microchi-
meric cells were enriched as a percentage of all micro-
chimeric cells, compared to autologous cells of that
phenotype as a percentage of all autologous immuno-
phenotyped cells. Muscle cells were excluded in this
analysis. An enrichment of microchimeric cells com-
pared to autologous cells could indicate their involve-
ment in disease pathogenesis. In most cases, the
proportion of microchimeric cells of a given phenotype
compared to all the microchimeric immunophenotyped
cells in the muscle tissue was significantly less than the
proportion of autologous cells with that phenotype as a
percentage of all autologous immunophenotyped cells
(Table 1). In JIIM muscle, except for CD45RA+ and
CD83+ cells, the proportion of microchimeric cells for
each lineage as a proportion of all microchimeric cells
was significantly less than the proportion of autologous
cells of that same phenotype. The proportion of micro-
chimeric cells that were CD45RA+ compared to all
microchimeric cells was similar to, but not greater than,
the proportion of autologous CD45RA+ cells compared
to all autologous immunophenotyped cells. In MD
biopsies, the proportion of microchimeric CD3+ and
Class II+ cells as a percentage of all microchimeric cells
was significantly less than their autologous counter-
parts, with a trend toward a lower frequency of micro-
chimeric cells in CD8+ and CD123+ lineages compared
to their autologous equivalents. In the control muscle
tissue, significantly fewer microchimeric cells were
found in CD3+, Class II+ and the CD25+ lineages com-
pared to these autologous lineages as a proportion of
the total autologous immunophenotyped cells, with a
trend toward fewer microchimeric cells of the CD8+
and CD123+ lineages.
Do microchimeric cells mediate tissue repair?
Others have proposed that microchimeric cells might
mediate tissue repair. In muscle diseases, they could
contribute to regenerating myofibers. Thus, we hypothe-
sized that in JIIM and MD the proportion of microchi-
meric myofiber nuclei would be enriched compared to
autologous myofiber nuclei. We stained 15 sections for
actin but found that the stain interfered with FISH, pos-
sibly due to the overabundance of actin within these
muscle sections. Consequently, we subsequently quanti-
fied maternally derived myofiber nuclei based on the
morphology of the nucleus and its location within the
fiber (Fig. 2, bottom). The density of microchimeric myo-
fiber nuclei was 0.01 ± 0.01 microchimeric cells/mm2 of
muscle tissue in JIIM, 0.07 ± 0.03/mm2 in MD, and
0.02 ± 0.01/mm2 in controls. MD biopsies had sig-
nificantly more microchimeric myofiber nuclei than
JIIM (p = 0.018). The number of microchimeric myo-
fiber nuclei did not differ between JIIM and controls
or between MD and controls (p = 0.33 and p = 0.18,
respectively). Like the phenotyped microchimeric cells,
we found significantly fewer microchimeric muscle nuclei
than autologous muscle nuclei in JIIM, MD and control
biopsies. The proportion of microchimeric myofiber nu-
clei was significantly less than the proportion of autolo-
gous myofiber nuclei. The percentage of microchimeric
myofibers compared with autologous myofibers from
the same group was 0.6 ± 0.6 % in JIIM (p = 0.002),
3.6 ± 1.2 % in MD (p < 0.001) and 2.5 ± 1.4 % in
controls (p = 0.0014) (see Fig. 2 for representative micro-
chimeric myofibers).
Fig. 3 Percentage of microchimeric cells at various muscle locations. Data are presented as mean of the percentage ± standard error of the
mean at each location for each diagnostic group. JIIM juvenile idiopathic inflammatory myopathy (n = 10), MD muscular dystrophy (n = 9),
N-IC noninflammatory controls (n = 10). *p = 0.014. (a) Perivascular location; (b) Perimysial location; (c) Endomysial location
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Discussion
Previously we found higher frequency and number of
microchimeric cells in the peripheral blood and muscle
tissue of JIIM patients compared to noninflammatory or
healthy control subjects, suggesting that microchimeric
cells may play a role in the pathogenesis of JIIM [4, 20].
One limitation in those studies was that we did not
phenotype the microchimeric cells in the tissues; how-
ever, we did find microchimeric cells in the CD4+ and
CD8+ lineages in peripheral blood [4]. The current study
further investigated microchimeric cells in JIIM, com-
pared with inflammatory but nonautoimmune muscle
disease (MD) and with noninflammatory control muscle
and examined the immunophenotypes of microchimeric
cells in muscle tissue. Our goals were to determine
whether microchimeric cells play a pathogenic role in
disease and/or whether they are involved in tissue repair.
Persistent microchimeric cells have been found in pa-
tients with other inflammatory diseases, suggesting that
these cells might be recruited nonspecifically to sites of
inflammation [7–10, 13, 14].
Compared with our prior study, we found a similar
frequency of JIIM muscle tissue samples containing
microchimeric cells and a similar overall quantity of
Table 1 Relationship between the frequencies of microchimeric versus autologous cells of a given immunophenotype
Phenotype JIIM MD NIC
% Autologous CD3+ cells of total autologousa 6.5 ± 2.3 9.9 ± 2.5 4.8 ± 2.7
% Microchimeric CD3+ cells of total microchimeric cellsb 0.3 ± 0.3 2.8 ± 1.8 10 ± 10
p = 0.06 (T) p = 0.04 p = 0.05
% Autologous CD4 cells of total autologous cells 16.8 ± 6.9 12.2 ± 5.3 8.4 ± 6.6
% Microchimeric CD4 cells of total microchimeric cells 2.2 ± 1.4 7.8 ± 2.0 0 ± 0
p = 0.03 p = 0.23 p = 0.12
% Autologous CD8 cells of total autologous cells 20.4 ± 5.0 12.6 ± 3.2 5.1 ± 3.2
% Microchimeric CD8 cells of total microchimeric cells 1.1 ± 0.6 6.5 ± 2.3 0 ± 0
p = 0.05 p = 0.09 p = 0.07
% Autologous Class II cells of total autologous cells 21.5 ± 8.1 51.6 ± 5.9 38.0 ± 11.0
% Microchimeric Class II cells of total microchimeric cells 1.7 ± 1.1 0.8 ± 0.7 20.0 ± 13.3
p = 0.04 p < 0.001 p = 0.02
% Autologous CD20 cells of total autologous cells 8.5 ± 4.4 2.7 ± 2.5 0 ± 0
% Microchimeric CD20 cells of total microchimeric cells 0 ± 0 0 ± 0 0 ± 0
p = 0.08 p = 0.3 p = NA
% Autologous CD83 cells of total autologous cells 0.1 ± 0.1 0.1 ± 0.1 0.2 ± 0.2
% Microchimeric CD83cells of total microchimeric cells 0 ± 0 0 ± 0 0 ± 0
p = 0.18 p = 0.17 p = 0.17
% Autologous CD25 cells of total autologous cells 16.2 ± 5.1 9.5 ± 3.4 6.4 ± 2.8
% Microchimeric CD25 cells of total microchimeric cells 0 ± 0 7.7 ± 2.9 0 ± 0
p = 0.01 p = 0.33 p = 0.02
% Autologous CD45RA cells of total autologous cells 2.3 ± 0.9 1.5 ± 0.4 3.2 ± 2.3
% Microchimeric CD45RA cells of total microchimeric cells 1.2 ± 1.1 0.9 ± 0.9 0 ± 0
p = 0.24 p = 0.26 p = 0.10
% Autologous CD45RO cells of total autologous cells 6.3 ± 2.4 4.1 ± 1.1 9.0 ± 4.4
% Microchimeric CD45RO cells of total microchimeric cells 0 ± 0 0 ± 0 0 ± 0
p = 0.03 p = 0.003 p = 0.06 (T)
% Autologous CD123 cells of total autologous cells 3.6 ± 1.1 1.9 ± 0.7 26.2 ± 12.2
% Microchimeric CD123 cells of total microchimeric cells 0.04 ± 0.02 0 ± 0 4.4 ± 2.3
p = 0.04 p = 0.06 (T) p = 0.06 (T)
Data are presented as mean ± standard error of the mean for each group
JIIM juvenile idiopathic inflammatory myopathy, MD muscular dystrophy, NIC noninflammatory controls; NA not available, T trend for significance
aTotal autologous cells consists of all phenotyped cells with XY probes
bTotal microchimeric cells consists of all cells with XX probes
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microchimeric cells in JIIM muscle tissue [4]. Here, we
also saw a similar concentration of microchimeric cells
in MD tissues, suggesting that this finding is not specific
to autoimmune diseases but may be generally associated
with overt inflammatory muscle disease. This suggests
that the number of inflammatory microchimeric cells re-
cruited to the site of inflammation does not depend on
the total number of inflammatory cells present. MD is a
genetic disease caused by mutations in dystrophin indu-
cing muscle fiber damage, with resultant muscle necrosis
and tissue inflammation [21], whereas the cause of JIIM
is unknown but presumed to result primarily from an
autoimmune-mediated destruction of myofibers and
muscle capillaries [17]. In both diseases, tissue destruc-
tion is mediated by T and B cells, and in JDM by
dendritic cells [22–24]. We were surprised to find
microchimeric cells also in a high proportion of control
muscle tissues, in contrast to our prior study [4]; how-
ever, in the prior study, only one muscle section was ex-
amined, whereas in the present study, ten sections from
each patient’s muscle tissue were examined. Microchi-
meric cells were not observed in every tissue section
from a given patient and thus overall were considered to
be a rare event.
To characterize the phenotype of microchimeric cells
in JIIM and MD, we stained muscle tissue for various
immunophenotypes. Overall, we detected few microchi-
meric cells within inflammatory phenotypes, and we did
not find microchimeric cells in B cell or dendritic cell
lineages, which are thought to be important in JIIM
pathogenesis. Of the T cell immunophenotypes, gener-
ally the concentration of microchimeric cells was greater
in MD tissues than in noninflammatory controls, and
typically T cells or activated T cells were not elevated in
JIIM muscle tissue. Microchimeric cells of a given pheno-
type did not occur more frequently than their autologous
counterparts in JIIM or MD muscle tissue, compared to
all microchimeric or immunophenotyped autologous cells.
In terms of location, the endomysial and perivascular re-
gions of the muscle showed similar numbers of microchi-
meric cells among the three groups. However, MD and
JPM tissues were more likely to have microchimeric cells
in the perimysium compared with controls. It is this sole
finding that weakly suggests that microchimeric cells
might play a pathogenic or reparative role.
We also found microchimeric cells in noninflamma-
tory tissues and in myofibers, not only in infiltrating in-
flammatory cells, suggesting that these cells are resident
in tissues regardless of inflammation. Tissues with ma-
ternal microchimeric cells include autoimmune and
nonautoimmune thyroid [25], pancreas in type I diabetes
[26], neonatal lupus heart muscle [27], tonsils and aden-
oids [28], cutaneous inflammatory diseases [29] and in-
flammatory bowel disease [30]. Normal tissues with
maternal microchimeric cells include heart [27], tonsils/
adenoids [28], skin diseases [29] and inflammatory bowel
disease [30]; albeit at lower levels than diseased tissue of
the same type, suggesting that a threshold number of
microchimeric cells might be necessary to drive disease.
However, in some instances microchimeric cells were
found at comparable numbers in healthy tissues [6].
One hypothesis proposed by other investigators is that
microchimeric cells might mediate tissue repair via
microchimeric stem cells. Initially we stained for muscle
fibers, but this staining procedure interfered with subse-
quent FISH. Therefore, we counted the numbers of
microchimeric nuclei that were apparently myofibers,
based on their morphological position and shape within
the muscle fiber, and compared them to the numbers of
autologous myofiber nuclei. We found significantly more
microchimeric muscle nuclei in MD than JIIM muscle,
but there were no significant differences between JIIM
and controls. However, each disease class had signifi-
cantly fewer microchimeric myonuclei than autologous
muscle nuclei. One caveat is that we do not know how
many myofibers were regenerated from autologous pro-
genitors during the disease process [27], and this study
was not designed to determine that. Overall, these re-
sults suggest that microchimeric myofibers are no more
frequent than microchimeric inflammatory cells in dis-
eased tissues, and that noninflammatory tissue resident
in microchimeric myofiber nuclei are present at higher
levels than observed in JIIM. This result suggests that
microchimeric cells are not enriched in muscle tissue in
any of these disease conditions, and that they do not
mediate tissue repair at an augmented rate compared to
autologous myofibers.
We stained one phenotype per FISH analysis for
microchimeric cells in the tissue, but we did not stain
for all cell phenotypes in the tissues. Consequently, we
may have missed a microchimeric cell phenotype(s) that
was noninflammatory, including muscle stem cells. We
did not analyze all inflammatory phenotypes, such as
macrophages, that are frequent in the inflammatory in-
filtrates of JIIM and MD muscle [22, 23], and some
microchimeric cells did not match any of the phenotypes
analyzed. The number of inflammatory cells in the JIIM
samples was comparable to previously published data
[22], and this suggests that the immunophenotyping was
not underrepresenting inflammatory cell phenotypes.
Furthermore, although we did not observe many differ-
ences in the phenotypic numbers of microchimeric cells
between disease groups, only one or a small number of
pathogenic microchimeric cells might be sufficient to
cause disease; however, we believe this is unlikely as
microchimeric cells were also present in the muscle tis-
sue of noninflammatory controls. In addition, we did not
examine the functionality of the microchimeric cells
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phenotyped and although microchimeric cells were found
in inflammatory cells of the controls, they may have been
quiescent, whereas in the inflammatory muscle diseases
they may be activated, indicated by different cytokine
profiles [31]. We did, however, investigate T cell activation
markers, such as Class II, CD25, and memory T cell
subsets, and did not detect more microchimeric cells in
JIIM muscle compared to noninflammatory controls,
and only MD had significantly more CD25 microchi-
meric cells. Finally, our sample sizes were relatively
small and the study may have been underpowered to
detect differences between groups.
Murine studies suggest that maternal microchimeric
cells are able to manipulate the fetal immune system
and promote the development of various Regulatory T
cells (Tregs) that are tolerant toward the noninherited
maternal antigens [32]. Additional studies using inbred
mice have also reported the trafficking of alloreactive T
cells in offspring and that the maternal cells can influ-
ence the fetal response to targeting specific tissues [33].
These studies were elegantly performed in mice, and
whether this same phenomenon occurs to the same
extent during human gestation leading to increased risk
for autoimmune diseases is yet to be proved. Currently,
no studies have been performed to determine whether
maternal microchimerism of cells that carry noninher-
ited shared epitopes place the JIIM cohort at a greater
risk for disease, like they apparently do for rheumatoid
arthritis [34]. HLA-DRB1*0301 in linkage with HLA-
DQA1*0501 confers the highest susceptibility for JIIM;
however, in contrast to previous studies [31], we found
that HLA-DQA*0501 was not significantly associated
with microchimerism [35]. Maternal microchimeric cell
transfer is a frequent occurrence during fetal develop-
ment [36], and these cells most likely distribute through-
out all the tissues and become embedded in the bone
marrow with the ability to differentiate into inflamma-
tory cells or stromal cells upon cell damage. Thus, the
presence of maternal microchimeric cells in tissues is
not surprising in light of the high number of normal
samples that were positive in our study and in other
studies [6, 37]. Our data support the findings of Ye et al.,
who also reported their controls being positive for mater-
nal microchimerism [6]. The presence of microchimeric
cells in the control tissues without inflammation suggests
that they are present either from fetal development if
stromal in nature, or are inflammatory cells trafficking
through the tissue. In contrast with Ye et al., we found the
presence of some microchimeric T cells, albeit at very low
percentages in our JDM samples. However, the direct role
of maternal microchimeric cells in human disease is still
not clear and against the complex genetic background of
humans may mean that the direct role of these cells in
autoimmunity may never be conclusively demonstrated.
Conclusions
Overall, our results indicate that microchimeric cells
likely do not play important pathogenic roles in auto-
immune or inflammatory muscle disease, nor are they
seemingly involved in mediating repair of muscle tissue.
Once differentiated, where there is inflammation, the
autologous cells, along with their microchimeric coun-
terparts, appear to be recruited to those sites in like
manner. This study suggests that microchimeric cells are
not part of the autoimmune pathogenesis in JIIM or the
primary inflammatory process in MD.
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